Sponsored Content
Question: Are third-party research trials showing good improvement in HLB symptoms with the use of ReMedium TI®?
Answer: There have been a number of research trials performed by the University of Florida Institute of Food and Agricultural Sciences (UF/IFAS) and U.S. Department of Agriculture-Agricultural Research Service (USDA-ARS) over the past couple of years. ReMedium TI® results have been very consistent with average yield increases of 30% in year one with additional yield benefits after two or more years of injection.
Data from Lukasz Stelinski’s UF/IFAS trials showed that ReMedium TI® injection significantly increased citrus yield in year one and year two. The yield benefit in year one calculated to a per acre profit of over $200, and in year two it was over $700 per acre. These values were calculated using the average prices received by the industry in each of the two years.
USDA-ARS provided a presentation to Florida Citrus Mutual in June 2025. One of the slides highlighted a trial of eight entries designed to be possible injection improvements or substitutes to oxytetracycline injections with ReMedium TI® as the check. Of the eight treatments, ReMedium TI® by itself had the highest yield benefit as well as the highest Brix level. The yield increase was similar to other trials, and the Brix was about 9.25%. The other trial treatments were closer to the 8.5% Brix level. In this trial, no added chemistry to ReMedium TI® increased yield or Brix.
This trial suggests that adding another chemistry to ReMedium TI® may not be the best choice at this time. There are other trials that show some improvement in Brix by adding chemistry, but this may require a ReMedium TI® label change depending on what the chemistry is. Label changes can be complicated and expensive.
We are looking forward to seeing more of the results from the data that will come in over the next couple of months. In the meantime, the current data seems to be saying that ReMedium TI® is the HLB therapy of choice for maximum return on investment.
Share this Post